First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Vertex Pharmaceuticals Incorporated

    VRTX · 19 developments mapped · last assessed 2026-09-28

    Market Ontology has mapped 19 macro, policy, and market developments to Vertex Pharmaceuticals Incorporated since 2026-08-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for VRTX yet, so no modelled value is shown. The VRTX valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run VRTX on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for VRTX. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Vertex reports positive Phase IIb inaxaplin results for kidney disease

      Direct clinical trial success, de-risking of pipeline asset, potential for significant new market entry.

      · Moves probability of success for inaxaplin, peak sales estimates for inaxaplin, discount rate (due to reduced risk)

    • Open question

      Vertex Pharmaceuticals Incorporated to Acquire Crinetics Pharmaceuticals, Inc.

      Direct acquisition of a target company, potential for pipeline expansion, integration costs, and dilution/cash outlay. Shareholder complaints against the target could introduce minor integration risks or delays.

      · Moves future growth rates (synergies, new product pipeline), cost of capital (if financing structure changes), terminal growth rate (if acquisition significantly alters long term outlook)

    What changed, by assumption

    Probability of success for pipeline assets
    • 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin
    • 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
    Probability of success for inaxaplin
    • 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney disease
    • 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD
    Peak sales estimates for casgevy
    • 2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy
    • 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+
    • 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    Future growth rates (synergies, new product pipeline)
    • 2026-08-19Vertex Pharmaceuticals Incorporated to Acquire Crinetics Pharmaceuticals, Inc.
    Probability of success pipeline
    • 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-19Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-08-19Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-08-19RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-28Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy Reviewwatch3-12m0.20
    2026-09-27Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total RevenueBullish3-12m0.20
    2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialBullish1-3m0.85
    2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseBullish1-5y0.90
    2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDBullish1-3m0.85
    2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinBullish1-3m0.90
    2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel PathwaysBullish1-3m0.60
    2026-09-14Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913watch1-5y0.10
    2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales JumpBullish3-12m0.60
    2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+Bullish3-12m0.70
    2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MBullish1-3m0.60
    2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy CasgevyBullish3-12m0.80